Intrathecal inoculation of mouse sarcoma 180 in the horse; production of heterologous tumor antibodies.

The research article discusses an experiment where horses were infected with mouse sarcoma 180 to produce antibodies against the tumor. These antibodies were then found to specifically target sarcoma 180 tumors in mice when tracked using a radioactive tracer.

Immunization and Recovery of Antibodies

• The research began by immunizing horses through repeated injections of suspensions of sarcoma 180 tumor into their spinal cord at the back of the cerebellum.
• These injections led to the production of heterologous antibodies, i.e., antibodies that recognize and react to the mouse-based sarcoma.
• The antibodies were later recovered from the cerebrospinal fluid of the immunized horses.

Complement Fixation Tests

• Complement fixation tests, which measure the ability of the antibodies to recognize and bind to a specific pathogen, were carried out on the cerebrospinal fluid from the immunized horses.
• These tests showed positive fixation for sarcoma 180 tumor – signifying that these antibodies were specifically able to recognize this mouse tumor.
• The fixation was said to be beyond the normal response seen for mouse heart and connective tissue, suggesting a higher specificity of the antibodies towards the tumor.

Tracer Experiments

• The researchers then fused the recovered antibodies with radioactive I-131, and subsequently injected them into mice hosting sarcoma 180 tumors.
• There was a preferential localization of these radioactive antibodies within the sarcoma 180 tumors thus signifying their ability to specifically target tumor cells.
• However, no such localization was observed in other types of spontaneous tumors (like carcinomas) in the mice, or in lymphosarcoma tumors in rats which further highlights the specificity of the produced antibodies towards the sarcoma 180 tumor.